M
Michael A. Sellitto
Researcher at Harvard University
Publications - 5
Citations - 181
Michael A. Sellitto is an academic researcher from Harvard University. The author has contributed to research in topics: Bruton's tyrosine kinase & Bone marrow. The author has an hindex of 2, co-authored 5 publications receiving 173 citations.
Papers
More filters
Journal ArticleDOI
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.
Yu-Tzu Tai,Betty Y. Chang,Sun-Young Kong,Sun-Young Kong,Mariateresa Fulciniti,Guang Yang,Yolanda Calle,Yiguo Hu,Jianhong Lin,Jianjun Zhao,Antonia Cagnetta,Michele Cea,Michael A. Sellitto,Mike Y Zhong,Qiuju Wang,Chirag Acharya,Daniel R. Carrasco,Joseph J. Buggy,Laurence Elias,Steven P. Treon,William Matsui,Paul G. Richardson,Nikhil C. Munshi,Nikhil C. Munshi,Kenneth C. Anderson +24 more
TL;DR: Functional sequelae of Btk activation mediating osteolysis and growth of MM cells are delineated, supporting evaluation of PCI-32765 as a novel therapeutic in MM.
Journal ArticleDOI
Targeting Brouton's Tyrosine Kinase with PCI-32765 Blocks Growth and Survival of Multiple Myeloma and Waldenstrom Macroglobulinemia Via Potent Inhibition of Osteoclastogenesis, Cytokines/Chemokine Secretion, and Myeloma Stem-Like Cells in the Bone Marrow Microenvironment
Yu-Tzu Tai,Betty Y. Chang,Sun-Young Kong,Mariateresa Fulciniti,Guang Yang,Yolanda Calle,Yiguo Hu,Jianhong Lin,Jianjun Zhao,Michele Cea,Antonia Cagnetta,Michael A. Sellitto,Michelle C. Chen,Zachary R. Hunter,Ruben D. Carrasco,Joseph J. Buggy,Laurence Elias,William Matsui,Steven P. Treon,Paul G. Richardson,Nikhil C. Munshi,Kenneth C. Anderson +21 more
TL;DR: Investigating effects of PCI-32765, an oral, potent, and selective Btk inhibitor with promising clinical activity in B-cell malignancies, on OC differentiation and function within MM bone marrow (BM) microenvironment, as well as on MM and WM cancer cells provides compelling evidence to target Btk in the BM milieu.
Journal ArticleDOI
Blockade of Nuclear Export Protein CRM1 (chromosomal region maintenance 1, XPO1) by a Novel, Potent and Selective CRM1 Inhibitor KPT-185 Induces Significant Antitumor Activity Against Human Multiple Myeloma
Sun-Young Kong,Yosef Landesman,Jana Jakubikova,Michael A. Sellitto,Antonia Cagnetta,Michele Cea,Michelle C. Chen,Francesca Cottini,Douglas W. McMillin,Chirag Acharya,William Senapedis,Sharon Shacham,Michael Kauffman,Dilara McCauley,Jean-Richard Saint-Martin,Nikhil C. Munshi,Paul G. Richardson,Kenneth C. Anderson,Yu-Tzu Tai +18 more
TL;DR: Gene expression profiling analysis using GEO database showed that CRM1 expression is significantly increased in CD138+ cells from MM patients versus monoclonal gammopathy of undetermined significance (MGUS) patients or normal donors, and a novel selectiveCRM1 inhibitor, KPT-185, in human MM cells was investigated.
Journal ArticleDOI
Immunomodulatory Effects of Histone Deacetylase 6 Inhibition in Suppressor Immune Cells in Multiple Myeloma
Gullu Gorgun,Teru Hideshima,Noopur Raje,Naoya Mimura,James E. Bradner,Diana Cirstea,Loredana Santo,Yu-Tzu Tai,Michael A. Sellitto,Yiguo Hu,Claire Fabre,Hiroto Ohguchi,Jiro Minami,Paul G. Richardson,Nikhil C. Munshi,Kenneth C. Anderson +15 more
TL;DR: Assessment of MDSCs in both peripheral blood and bone marrow of patients with MM compared to healthy donors showed a significant increase in CD14−CD11b+HLA-DRlowCD15+ MDSC numbers, which represent a significant barrier to current anti-tumor therapeutic strategies.
myeloma targeting tumor in the bone marrow microenvironment in multiple Bruton tyrosine kinase inhibition is a novel therapeutic strategy
P. Treon,William Matsui,Paul G. Richardson,Nikhil C. Munshi,Qiuju Wang,Chirag Acharya,Daniel R. Carrasco,Joseph J. Buggy,Laurence Elias,Jianhong Lin,Jianjun Zhao,Antonia Cagnetta,Michele Cea,Michael A. Sellitto,Mike Y. Yu-Tzu Tai,Betty Chang,Sun-Young Kong,Mariateresa Fulciniti,Guang Yang,Yolanda Calle +19 more